Clinical trial · Observational
18F-Fluorocholine PET/CT in Medullary Thyroid Cancer
Diagnostic Value of 18F-Fluorocholine PET/CT for the Detection of Medullary Thyroid Cancer
NCT03643055CI-TRIAL-00048101unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the diagnostic accuracy of 18F-Fluorocholine PET/CT for the detection of medullary thyroid cancer in patients with primary and recurrent disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Medullary Thyroid Cancer | Thyroid Gland Medullary Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-fluorocholine PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- MTC 18F-fluorocholine PET/CT
- description
- Patients with medullary thyroid cancer imaged using 18F-fluorocholine PET/CT.
- interventionNames
- Diagnostic Test: 18F-fluorocholine PET/CT
Primary outcomes (2)
- measure
- Sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy in primary medullary thyroid cancer
- timeFrame
- 1 month
- description
- Ability to detect primary medullary thyroid cancer (primary, nodal and metastatic lesions) in correlation with histopathological and/or conventional imaging data.
- measure
- Sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy in recurrent medullary thyroid cancer
- timeFrame
- 3 months
- description
- Ability to detect recurrent medullary thyroid cancer (nodal and distant metastatic lesions) in correlation with histopathological and/or conventional imaging data.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with medullary thyroid cancer (sporadic or hereditary form). * Patients with newly diagnosed MTC for primary staging (based on fine needle aspiration cytology results). * Patients with suspicion of MTC recurrence for re-staging (based on biochemical, conventional imaging or clinical examination). * Patients with metastatic MTC on systemic therapy for disease activity assessment. Exclusion Criteria: * Pregnancy. * Patient with any PET/CT-scan exam contraindication (eg. severe claustrophobia).
References
Publications (0)
Data not yet available
No reference posted for this study.